MCID: OVR078
MIFTS: 47

Ovarian Cancer, Somatic malady

Categories: Genetic diseases (common), Cancer diseases

Aliases & Classifications for Ovarian Cancer, Somatic

About this section

Aliases & Descriptions for Ovarian Cancer, Somatic:

Name: Ovarian Cancer, Somatic 50 23 12
Adenocarcinoma, Ovarian, Somatic 50 12
Ovarian Carcinoma, Somatic 50
 
Epithelial Ovarian Cancer 68
Ovarian Cancer 68
Oc 68

Characteristics:

HPO:

62
ovarian cancer, somatic:
Inheritance: autosomal dominant inheritance


Classifications:



External Ids:

OMIM50 167000
MeSH37 D010051

Summaries for Ovarian Cancer, Somatic

About this section
OMIM:50 Ovarian cancer, the leading cause of death from gynecologic malignancy, is characterized by advanced presentation with... (167000) more...

MalaCards based summary: Ovarian Cancer, Somatic, also known as adenocarcinoma, ovarian, somatic, is related to prostate cancer and megalencephaly-capillary malformation-polymicrogyria syndrome, somatic, and has symptoms including abnormality of metabolism/homeostasis, breast carcinoma and ovarian papillary adenocarcinoma. An important gene associated with Ovarian Cancer, Somatic is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha), and among its related pathways are RHO GTPases activate IQGAPs and Signaling events mediated by VEGFR1 and VEGFR2. Affiliated tissues include breast, and related mouse phenotypes are no phenotypic analysis and muscle.

UniProtKB/Swiss-Prot:68 Ovarian cancer: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease.

Related Diseases for Ovarian Cancer, Somatic

About this section

Diseases related to Ovarian Cancer, Somatic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 107)
idRelated DiseaseScoreTop Affiliating Genes
1prostate cancer27.2AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2
2megalencephaly-capillary malformation-polymicrogyria syndrome, somatic10.6MUT, PIK3CA
3cowden syndrome 510.6MUT, PIK3CA
4spermatogenic failure 610.6MUT, PIK3CA
5vaginal adenosarcoma10.5ERBB2, PIK3CA
6trigeminal nerve disease10.5BRCA1, ERBB2
7hemochromatosis type 210.4CTNNB1, PIK3CA
8congenital pulmonary veins atresia or stenosis10.4BRCA1, BRCA2
9baraitser-winter cerebrofrontofacial syndrome10.4BRCA2, PIK3CA
10pregnancy adenoma10.4CDH1, ERBB2
11plethora of newborn10.4CDH1, CTNNB1
12bronchopulmonary dysplasia10.4BRCA1, BRCA2
13malignant hyperthermia susceptibility type 210.4KRAS, PIK3CA
14autoimmune disease of blood10.4BRCA1, BRCA2
15selective ige deficiency disease10.4BRCA1, BRCA2
16epilepsy, progressive myoclonic 1b10.4CTNNB1, PARK2
17diffuse intrinsic pontine glioma10.4CDH1, ERBB2
18ovarian small cell carcinoma10.4CTNNB1, ERBB2, PIK3CA
19lethal congenital contracture syndrome 710.3BRCA1, BRCA2
20cystinosis, nephropathic10.3ERBB2, NEU1
21retinitis10.3ERBB2, PIK3CA
22vocal cord scarring10.3AKT1, CTNNB1, PIK3CA
23microscopic colitis10.3AKT1, CTNNB1, PIK3CA
24gliomatosis peritonei10.3AKT1, ERBB2, PIK3CA
25gastric squamous cell carcinoma10.3CDH1, ERBB2
26fat necrosis of breast10.3BRCA1, BRCA2
27amyloid tumor10.2BRCA1, BRCA2
28ovarian brenner tumor10.2BRCA1, BRCA2
29papillary adenofibroma10.2BRCA1, BRCA2, PIK3CA
30osteopetrosis10.2
31mediastinal neurilemmoma10.2BRCA1, BRCA2, PIK3CA
32fallopian tube germ cell cancer10.2BRCA1, BRCA2
33breast malignant phyllodes tumor10.2CDH1, CTNNB1, ERBB2
34villous adenoma10.2AKT1, CDH1, CTNNB1
35complex lethal osteochondrodysplasia10.1CDH1, PIK3CA
36lobular neoplasia10.1CDH1, CTNNB1, ERBB2
37chorea, hereditary benign10.1CDH1, CTNNB1, PIK3CA
38lingual goiter10.1AKT1, BRCA2, CTNNB1
39nasopharyngeal carcinoma10.1BRCA1, BRCA2, PIK3CA
40cutaneous lupus erythematosus10.1BRCA1, BRCA2, ERBB2
41cervical serous adenocarcinoma10.1BRCA1, BRCA2, ERBB2
42gastric cancer risk after h. pylori infection10.1CDH1, KRAS
43breast papillary carcinoma10.1ERBB2, KRAS, PIK3CA
44dermatosis papulosa nigra10.1ERBB2, KRAS, PIK3CA
45leiomyosarcoma10.1BRCA1, BRCA2, ERBB2
46distal monosomy 9p10.1BRCA1, BRCA2, ERBB2
47adenosquamous carcinoma10.1ERBB2, KRAS, PIK3CA
48lung carcinoma in situ10.1BRCA1, BRCA2, ERBB2
49epidermal nevus, somatic10.1KRAS, MUT, PIK3CA
50pineal region meningioma10.0BRCA1, BRCA2, ERBB2

Comorbidity relations with Ovarian Cancer, Somatic via Phenotypic Disease Network (PDN):


Acute CystitisDeficiency Anemia
Fallopian Tube CarcinomaHydronephrosis
Intestinal ObstructionNeutropenia
Paralytic IleusProtein-Energy Malnutrition
Uterine FibroidPeritoneum Cancer

Graphical network of the top 20 diseases related to Ovarian Cancer, Somatic:



Diseases related to ovarian cancer, somatic

Symptoms for Ovarian Cancer, Somatic

About this section

Symptoms by clinical synopsis from OMIM:

167000

Clinical features from OMIM:

167000

HPO human phenotypes related to Ovarian Cancer, Somatic:

id Description Frequency HPO Source Accession
1 abnormality of metabolism/homeostasis HP:0001939
2 breast carcinoma HP:0003002
3 ovarian papillary adenocarcinoma HP:0006774
4 dysgerminoma HP:0100621

Drugs & Therapeutics for Ovarian Cancer, Somatic

About this section

Drugs for Ovarian Cancer, Somatic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
OlaparibPhase 4, Phase 3117763113-22-023725625
Synonyms:
4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-one
4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one
4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
763113-22-0
937799-91-2
AKOS005145764
AZD 2281
AZD-2281
AZD2281
 
Acylpiperazine analogue, 47
CHEMBL521686
EC-000.2324
EN002690
FT-0083489
KU-0059436
KU-59436
Olaparib
Olaparib, KU-0059436, AZD2281, KU0059436, AZD2281
S1060_Selleck
olaparib
2
PaclitaxelPhase 2269133069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nab-paclitaxel
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
3
FulvestrantPhase 2182129453-61-8104741, 17756771
Synonyms:
(7R,13S,17S)-13-methyl-7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
(7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
(7R,8S,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
(7alpha,17beta)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-3,17-diol
129453-61-8
7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)estra-1,3,5(10)-triene-3,17-diol
7alpha-(9-((4,4,5,5,5,-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol
7alpha-(9-((4,4,5,5,5-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol
7alpha-[9[(4,4,5,5,5-Pentafluropentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene-3, 17 beta diol
AC-4693
AC1L2XEN
AstraZeneca brand of fulvestrant
BIDD:ER0348
BIDD:PXR0136
C070081
C32H47F5O3S
CCRIS 8741
CHEBI:404798
CHEMBL1358
CID104741
D01161
DB00947
Faslodex
Faslodex (TN)
 
Faslodex(ICI 182,780)
Faslodex, ICI 182780, Fulvestrant
Fulvestrant
Fulvestrant (JAN/USAN/INN)
Fulvestrant [USAN]
HMS2090N22
HSDB 7658
I06-1109
ICI 182,780
ICI 182,789
ICI-182780
Ici 182780
LS-64781
NCGC00164789-02
NSC719276
S1191_Selleck
UNII-22X328QOC4
ZD 182780
ZD-182780
ZD-9238
ZM 182780
ZM-182780
fulvestrant
nchembio.168-comp5
nchembio.76-comp5
nchembio775-comp4
4
RucaparibPhase 1, Phase 2119931954
Synonyms:
AG-014699
 
AG014699
PF-01367338
rucaparib
5KavaNutraceutical1379000-38-8

Interventional clinical trials:

(show all 12)
idNameStatusNCT IDPhase
1To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian CancerRecruitingNCT02476968Phase 4
2Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes MutationsWithdrawnNCT02392676Phase 3
3An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene AmplificationRecruitingNCT01953926Phase 2
4A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)Active, not recruitingNCT01482715Phase 1, Phase 2
5Phase II Study of BMN 673Active, not recruitingNCT02286687Phase 2
6Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma - Study of Sensitivity and SpecificityRecruitingNCT02518256
7Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in Early Onset Cancers With Sporadic or Hereditary PresentationRecruitingNCT02664389
8A Study of Long-Term Responders on OlaparibRecruitingNCT02489058
9Clinical Significance of Germline BRCA MutationsRecruitingNCT00579488
10Prevalence of BRCA in Patients With Ovarian CancerActive, not recruitingNCT02222883
11Live After an Epithelial Ovarian Cancer: Multidisciplinary Assessment of Effects and Long-term Remission in Patients Needs.Active, not recruitingNCT02323568
12EXPRESS: EXcePtional RESponSe - Exceptional and Unexpected Response to Targeted TherapiesActive, not recruitingNCT02701907

Search NIH Clinical Center for Ovarian Cancer, Somatic

Genetic Tests for Ovarian Cancer, Somatic

About this section

Genetic tests related to Ovarian Cancer, Somatic:

id Genetic test Affiliating Genes
1 Ovarian Cancer, Somatic23 AKT1, PIK3CA, ERBB2

Anatomical Context for Ovarian Cancer, Somatic

About this section

MalaCards organs/tissues related to Ovarian Cancer, Somatic:

34
Breast

Animal Models for Ovarian Cancer, Somatic or affiliated genes

About this section

MGI Mouse Phenotypes related to Ovarian Cancer, Somatic:

39 (show all 20)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00030128.1CDH1, CTNNB1, KRAS, NEU1, OPCML, PARK2
2MP:00053697.8AKT1, BRCA1, CTNNB1, ERBB2, KRAS, NEU1
3MP:00028737.7AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2
4MP:00053897.7AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2
5MP:00053817.7BRCA1, BRCA2, CDH1, CTNNB1, ERBB2, KRAS
6MP:00053887.7AKT1, BRCA1, CTNNB1, ERBB2, KRAS, MUT
7MP:00053877.2AKT1, BRCA1, BRCA2, CDH1, CTNNB1, KRAS
8MP:00053717.2BRCA1, BRCA2, CTNNB1, ERBB2, KRAS, PALB2
9MP:00053797.0AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2
10MP:00053906.9AKT1, BRCA1, BRCA2, CTNNB1, ERBB2, KRAS
11MP:00020066.8AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2
12MP:00053806.8AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2
13MP:00053866.5AKT1, BRCA1, BRCA2, CTNNB1, ERBB2, KRAS
14MP:00107716.2AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2
15MP:00053766.0AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2
16MP:00053855.9AKT1, BRCA1, CDH1, CTNNB1, ERBB2, KRAS
17MP:00036315.9AKT1, BRCA1, BRCA2, CTNNB1, ERBB2, KRAS
18MP:00053845.6AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2
19MP:00107685.5AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2
20MP:00053785.3AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2

Publications for Ovarian Cancer, Somatic

About this section

Variations for Ovarian Cancer, Somatic

About this section

UniProtKB/Swiss-Prot genetic disease variations for Ovarian Cancer, Somatic:

68
id Symbol AA change Variation ID SNP ID
1BRCA1p.Cys61GlyVAR_007757rs28897672
2BRCA1p.Cys1697ArgVAR_020702
3BRCA1p.Arg1699TrpVAR_075666
4CTNNB1p.Ser37CysVAR_017625rs121913403
5CTNNB1p.Thr41IleVAR_017630rs121913413
6OPCMLp.Pro95ArgVAR_055421rs137852691
7PIK3CAp.His1047ArgVAR_026192rs121913279

Clinvar genetic disease variations for Ovarian Cancer, Somatic:

5 (show all 42)
id Gene Variation Type Significance SNP ID Assembly Location
1KRASNM_033360.3(KRAS): c.35G> A (p.Gly12Asp)single nucleotide variantPathogenicrs121913529GRCh37Chr 12, 25398284: 25398284
2KRASNM_033360.3(KRAS): c.34G> A (p.Gly12Ser)single nucleotide variantPathogenicrs121913530GRCh37Chr 12, 25398285: 25398285
3PALB2NM_024675.3(PALB2): c.1050_1053delAACA (p.Thr351Argfs)deletionPathogenicrs515726060GRCh38Chr 16, 23635493: 23635496
4PIK3CANM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg)single nucleotide variantPathogenicrs121913279GRCh37Chr 3, 178952085: 178952085
5PIK3CANM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys)single nucleotide variantPathogenicrs104886003GRCh37Chr 3, 178936091: 178936091
6PIK3CANM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala)single nucleotide variantPathogenicrs121913274GRCh37Chr 3, 178936092: 178936092
7ERBB2NM_001005862.2(ERBB2): c.2480A> G (p.Asn827Ser)single nucleotide variantPathogenicrs28933370GRCh37Chr 17, 37881378: 37881378
8AKT1NM_005163.2(AKT1): c.49G> A (p.Glu17Lys)single nucleotide variantPathogenicrs121434592GRCh37Chr 14, 105246551: 105246551
9NC_012920.1: m.14743A> Gsingle nucleotide variantLikely pathogenicrs527236161GRCh37Chr MT, 14743: 14743
10MT-CYBNC_012920.1: m.14753C> Tsingle nucleotide variantLikely pathogenicrs527236162GRCh38Chr MT, 14753: 14753
11MT-CYBNC_012920.1: m.14784T> Csingle nucleotide variantLikely pathogenicrs527236163GRCh37Chr MT, 14784: 14784
12MT-CYBNC_012920.1: m.15058C> Tsingle nucleotide variantLikely pathogenicrs527236171GRCh37Chr MT, 15058: 15058
13MT-CYBNC_012920.1: m.15098A> Gsingle nucleotide variantLikely pathogenicrs527236172GRCh37Chr MT, 15098: 15098
14MT-CYBNC_012920.1: m.15314G> Asingle nucleotide variantLikely pathogenicrs527236176GRCh37Chr MT, 15314: 15314
15MT-CYBNC_012920.1: m.15328A> Gsingle nucleotide variantLikely pathogenicrs527236178GRCh37Chr MT, 15328: 15328
16MT-CYBNC_012920.1: m.15334C> Tsingle nucleotide variantLikely pathogenicrs527236179GRCh37Chr MT, 15334: 15334
17MT-CYBNC_012920.1: m.15363A> Gsingle nucleotide variantLikely pathogenicrs527236182GRCh37Chr MT, 15363: 15363
18MT-CYBNC_012920.1: m.15453T> Csingle nucleotide variantLikely pathogenicrs527236184GRCh37Chr MT, 15453: 15453
19MT-CYBNC_012920.1: m.15459C> Tsingle nucleotide variantLikely pathogenicrs527236186GRCh37Chr MT, 15459: 15459
20MT-CYBNC_012920.1: m.15511T> Csingle nucleotide variantLikely pathogenicrs527236188GRCh37Chr MT, 15511: 15511
21MT-CYBNC_012920.1: m.15884G> Asingle nucleotide variantLikely pathogenicrs527236195GRCh37Chr MT, 15884: 15884
22MT-TTNC_012920.1: m.15890C> Asingle nucleotide variantLikely pathogenicrs527236196GRCh37Chr MT, 15890: 15890
23MT-TTNC_012920.1: m.15928G> Asingle nucleotide variantLikely pathogenicrs527236198GRCh37Chr MT, 15928: 15928
24MT-TTNC_012920.1: m.15932T> Gsingle nucleotide variantLikely pathogenicrs527236199GRCh37Chr MT, 15932: 15932
25MT-TTNC_012920.1: m.15943T> Csingle nucleotide variantLikely pathogenicrs527236200GRCh37Chr MT, 15943: 15943
26MT-CYBNC_012920.1: m.15061A> Gsingle nucleotide variantLikely pathogenicrs527236205GRCh37Chr MT, 15061: 15061
27MT-CYBNC_012920.1: m.15148G> Asingle nucleotide variantLikely pathogenicrs527236206GRCh37Chr MT, 15148: 15148
28MT-CYBNC_012920.1: m.15259C> Tsingle nucleotide variantLikely pathogenicrs527236207GRCh37Chr MT, 15259: 15259
29MT-CYBNC_012920.1: m.15431G> Asingle nucleotide variantLikely pathogenicrs193302993GRCh37Chr MT, 15431: 15431
30MT-CYBNC_012920.1: m.15452C> Asingle nucleotide variantLikely pathogenicrs193302994GRCh37Chr MT, 15452: 15452
31MT-CYBNC_012920.1: m.15607A> Gsingle nucleotide variantLikely pathogenicrs193302996GRCh37Chr MT, 15607: 15607
32MT-CYBNC_012920.1: m.15670T> Csingle nucleotide variantLikely pathogenicrs193302997GRCh37Chr MT, 15670: 15670
33CTNNB1NM_001904.3(CTNNB1): c.110C> G (p.Ser37Cys)single nucleotide variantLikely pathogenic, Pathogenicrs121913403GRCh37Chr 3, 41266113: 41266113
34PIK3CANM_006218.3(PIK3CA): c.1624G> A (p.Glu542Lys)single nucleotide variantPathogenicrs121913273GRCh37Chr 3, 178936082: 178936082
35PIK3CANM_006218.3(PIK3CA): c.1258T> C (p.Cys420Arg)single nucleotide variantPathogenicrs121913272GRCh37Chr 3, 178927980: 178927980
36BRCA1NM_007294.3(BRCA1): c.1687C> T (p.Gln563Ter)single nucleotide variantPathogenicrs80356898GRCh37Chr 17, 41245861: 41245861
37BRCA2NM_000059.3(BRCA2): c.5682C> G (p.Tyr1894Ter)single nucleotide variantPathogenicrs41293497GRCh37Chr 13, 32914174: 32914174
38PIK3CANM_006218.3(PIK3CA): c.1637A> G (p.Gln546Arg)single nucleotide variantPathogenicrs397517201GRCh37Chr 3, 178936095: 178936095
39BRCA1NM_007294.3(BRCA1): c.5095C> T (p.Arg1699Trp)single nucleotide variantPathogenicrs55770810GRCh37Chr 17, 41215948: 41215948
40PARK2PARK2, DELdeletionPathogenic
41OPCMLNM_001012393.2(OPCML): c.263C> G (p.Pro88Arg)single nucleotide variantPathogenicrs137852691GRCh37Chr 11, 132527098: 132527098
42RRAS2NM_001177314.1(RRAS2): c.110A> T (p.Gln37Leu)single nucleotide variantPathogenicrs113954997GRCh37Chr 11, 14316390: 14316390

Expression for genes affiliated with Ovarian Cancer, Somatic

About this section
Search GEO for disease gene expression data for Ovarian Cancer, Somatic.

Pathways for genes affiliated with Ovarian Cancer, Somatic

About this section

Pathways related to Ovarian Cancer, Somatic according to GeneCards Suite gene sharing:

(show top 50)    (show all 66)
idSuper pathwaysScoreTop Affiliating Genes
19.7CDH1, CTNNB1
2
Show member pathways
9.6AKT1, CTNNB1, PIK3CA
39.6AKT1, CTNNB1, PIK3CA
49.6AKT1, ERBB2, PIK3CA
5
Show member pathways
9.6AKT1, ERBB2, PIK3CA
69.5AKT1, BRCA1, CTNNB1
79.5AKT1, BRCA1, CTNNB1
89.5AKT1, CDH1, PIK3CA
99.5AKT1, CDH1, PIK3CA
109.4CDH1, CTNNB1, PIK3CA
119.4CDH1, CTNNB1, PIK3CA
129.3CDH1, CTNNB1, ERBB2
139.3AKT1, KRAS, PIK3CA
149.3AKT1, KRAS, PIK3CA
15
Show member pathways
9.3AKT1, KRAS, PIK3CA
169.2AKT1, CTNNB1, KRAS
17
Show member pathways
9.2AKT1, CTNNB1, ERBB2, PIK3CA
189.2AKT1, CDH1, CTNNB1, PIK3CA
199.1AKT1, CDH1, ERBB2, PIK3CA
209.1CDH1, CTNNB1, KRAS
219.0AKT1, CDH1, CTNNB1, ERBB2
229.0CDH1, ERBB2, KRAS
239.0AKT1, CTNNB1, KRAS, PIK3CA
249.0AKT1, CTNNB1, KRAS, PIK3CA
259.0AKT1, CTNNB1, KRAS, PIK3CA
26
Show member pathways
8.9AKT1, ERBB2, KRAS, PIK3CA
278.9AKT1, ERBB2, KRAS, PIK3CA
28
Show member pathways
8.9AKT1, ERBB2, KRAS, PIK3CA
29
Show member pathways
8.9AKT1, ERBB2, KRAS, PIK3CA
30
Show member pathways
8.9AKT1, ERBB2, KRAS, PIK3CA
318.9BRCA1, ERBB2, KRAS, PIK3CA
32
Show member pathways
8.9AKT1, CTNNB1, ERBB2, KRAS
338.8AKT1, CDH1, CTNNB1, KRAS
348.8AKT1, CDH1, CTNNB1, KRAS
35
Show member pathways
8.8BRCA1, BRCA2, PALB2
36
Show member pathways
8.8BRCA1, BRCA2, PALB2
37
Show member pathways
8.7AKT1, BRCA1, CTNNB1, KRAS, PIK3CA
38
Show member pathways
8.6AKT1, CTNNB1, ERBB2, KRAS, PIK3CA
398.6AKT1, CTNNB1, ERBB2, KRAS, PIK3CA
40
Show member pathways
8.6AKT1, CTNNB1, ERBB2, KRAS, PIK3CA
41
Show member pathways
8.5AKT1, CDH1, CTNNB1, KRAS, PIK3CA
42
Show member pathways
8.5AKT1, BRCA1, CDH1, KRAS, PIK3CA
43
Show member pathways
8.4AKT1, BRCA2, ERBB2, KRAS, PIK3CA
44
Show member pathways
8.2AKT1, CDH1, CTNNB1, ERBB2, KRAS, PIK3CA
45
Show member pathways
8.2AKT1, CDH1, CTNNB1, ERBB2, KRAS, PIK3CA
46
Show member pathways
8.2AKT1, CDH1, CTNNB1, ERBB2, KRAS, PIK3CA
477.9AKT1, BRCA1, BRCA2, CDH1, CTNNB1, KRAS
487.8AKT1, BRCA1, BRCA2, CTNNB1, ERBB2, KRAS
497.6AKT1, BRCA2, CDH1, CTNNB1, ERBB2, KRAS
50
Show member pathways
7.3AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2

GO Terms for genes affiliated with Ovarian Cancer, Somatic

About this section

Cellular components related to Ovarian Cancer, Somatic according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1flotillin complexGO:001660010.2CDH1, CTNNB1
2catenin complexGO:001634210.2CDH1, CTNNB1
3apical junction complexGO:004329610.2CDH1, CTNNB1
4protein complexGO:00432348.9AKT1, BRCA1, BRCA2, CTNNB1, PARK2
5plasma membraneGO:00058867.0AKT1, BRCA1, CDH1, CTNNB1, ERBB2, KRAS

Biological processes related to Ovarian Cancer, Somatic according to GeneCards Suite gene sharing:

(show all 27)
idNameGO IDScoreTop Affiliating Genes
1negative regulation of release of cytochrome c from mitochondriaGO:009020110.5AKT1, PARK2
2protein K6-linked ubiquitinationGO:008502010.4BRCA1, PARK2
3vasculature developmentGO:000194410.4CTNNB1, PIK3CA
4DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorGO:000697810.2BRCA1, BRCA2
5regulation of myelinationGO:003164110.2AKT1, CTNNB1
6chordate embryonic developmentGO:004300910.2BRCA1, BRCA2
7cellular response to lithium ionGO:007128510.1CDH1, CTNNB1
8regulation of phosphatidylinositol 3-kinase signalingGO:001406610.1AKT1, ERBB2, PIK3CA
9striated muscle cell differentiationGO:005114610.1AKT1, KRAS
10phosphatidylinositol-mediated signalingGO:004801510.1AKT1, ERBB2, PIK3CA
11negative regulation of neuron deathGO:190121510.0AKT1, CTNNB1, PARK2
12positive regulation of histone H3-K4 methylationGO:00515719.9BRCA1, CTNNB1
13positive regulation of nitric-oxide synthase activityGO:00510009.9AKT1, KRAS
14epithelial tube branching involved in lung morphogenesisGO:00604419.9CTNNB1, KRAS
15cellular response to growth factor stimulusGO:00713639.9AKT1, CTNNB1, ERBB2
16cellular response to indole-3-methanolGO:00716819.8BRCA1, CDH1, CTNNB1
17inner cell mass cell proliferationGO:00018339.7BRCA2, PALB2
18liver developmentGO:00018899.6CTNNB1, KRAS, PIK3CA
19ERBB2 signaling pathwayGO:00381289.4AKT1, ERBB2, KRAS, PIK3CA
20double-strand break repair via homologous recombinationGO:00007249.4BRCA1, BRCA2, PALB2
21chromosome breakageGO:00310529.4BRCA1, BRCA2, PALB2
22negative regulation of neuron apoptotic processGO:00435249.2KRAS, PARK2, PIK3CA
23strand displacementGO:00007329.1BRCA1, BRCA2, PALB2
24DNA synthesis involved in DNA repairGO:00007319.1BRCA1, BRCA2, PALB2
25response to estradiolGO:00323559.0BRCA1, BRCA2, CTNNB1
26cell proliferationGO:00082839.0AKT1, BRCA2, CTNNB1, ERBB2
27positive regulation of gene expressionGO:00106288.5BRCA1, CTNNB1, ERBB2, KRAS, PARK2

Molecular functions related to Ovarian Cancer, Somatic according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1GTPase activating protein bindingGO:003279410.1AKT1, CDH1
2enzyme bindingGO:00198999.2AKT1, BRCA1, CTNNB1, PARK2

Sources for Ovarian Cancer, Somatic

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
25GTR
26HGMD
27HMDB
28ICD10
29ICD10 via Orphanet
30ICD9CM
31IUPHAR
32KEGG
35MedGen
37MeSH
38MESH via Orphanet
39MGI
42NCI
43NCIt
44NDF-RT
47NINDS
48Novoseek
50OMIM
51OMIM via Orphanet
55PubMed
56QIAGEN
61SNOMED-CT via Orphanet
65Tumor Gene Family of Databases
66UMLS
67UMLS via Orphanet